Recent news on Viramune

Boehringer Ingelheim Further Intensifies Fight Against AIDS  -  May 19, 2007
Medical News Today (press release),In order to further improve access to its anti-HIV drug Viramune (nevirapine) in developing countries Boehringer Ingelheim has amended its policy of

Boehringer Ingelheim initiates international head-to-head HIV/AIDS ...  -  May 17, 2007
WebWire (press release),Viramune® dosed twice daily is proven to be an effective, tolerable and durable treatment option with a favourable lipid profile. In ArTEN, Viramune® will

Boehringer Ingelheim further intensifies fight against AIDS  -  May 15, 2007
PharmaLive.com (press release),INGELHEIM, Germany, 15 May 2007 - In order to further improve access to its anti-HIV drug Viramune® (nevirapine) in developing countries Boehringer

Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS ...  -  May 9, 2007
Juraforum.de,VIRAMUNE dosed twice daily is provento be an effective, tolerable and durable treatment option with afavourable lipid profile. In ArTEN, VIRAMUNE will be

Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS ...  -  May 9, 2007
Earthtimes.orgVIRAMUNE dosed twice daily is proven to bean effective, tolerable and durable treatment option with a favourable lipidprofile. In ArTEN, VIRAMUNE will be

Boehringer cuts nevirapine price for developing world  -  May 15, 2007
Aidsmap,Boehringer-Ingelheim is to cut the price of its antiretroviral drug nevirapine (Viramune) by 50% in low-income countries, the company’s chairman has told

Boehringer To Reduce Price Of Antiretroviral Nevirapine In Low ...  -  May 18, 2007
Medical News Today (press release),German pharmaceutical company Boehringer Ingelheim will reduce the price of its antiretroviral drug nevirapine, sold under the brand name Viramune,

Boehringer Ingelheim launches HIV drug trial  -  May 10, 2007
Forbes,FRANKFURT (Thomson Financial) - Boehringer Ingelheim GmbH said it has begun enrolment for a trial to test the safety and efficacy of AIDS treatment Viramune

International panel issues new HIV/HCV co-infection guidelines  -  May 24, 2007
Aidsmap,Certain nucleoside analogues, notably ddI and d4T (Zerit), can cause mitochondrial toxicity (which can lead to liver steatosis), nevirapine (Viramune) can

HIV resistance mutations common but CXCR4 rare among untreated US ...  -  May 22, 2007
Aidsmap,Resistance to nevirapine (Viramune), delavirdine (Rescriptor), stavudine (Zerit), efavirenz (Sustiva), zidovudine (Retrovir), and nelfinavir (Viracept) were

Doctors recognized for fighting AIDS in Africa  -  May 19, 2007
Allentown Morning Call,...the testing program was well received, and they expanded the program to include administration of the drug Viramune to HIV-positive pregnant mothers.

No major metabolic differences between PI-based and NNRTI-based ...  -  Apr 29, 2007
Aidsmap,Efavirenz (Sustiva Viramune) was used as frequently. d4T (Zerit, stavudine) was also in common use, in about 36% of all participants.

Some HIV Drugs May Up Heart Risk  -  Apr 25, 2007
WebMDExamples of this type of drug include Viramune, Sustiva, and Rescriptor. The study doesn't prove that protease inhibitors cause heart attacks.

Some HIV Drugs May Up Heart Risk  -  26 Apr 2007
WebMDExamples of this type of drug include Viramune, Sustiva, and Rescriptor. The study doesn't prove that protease inhibitors cause heart attacks.

CROI 2007: A great leap forward  -  Mar 21, 2007
NAPWA,But there are only three approved drugs in the class – nevirapine (Viramune), efavirenz (Stocrin) and the rarely-used delavirdine (Rescriptor) – and they

CROI: Remission of Kaposi's sarcoma seen in rural Uganda when HIV ...  -  Mar 12, 2007
Aidsmap,The primary ART regimen was 3TC (lamivudine, Epivir), d4T (stavudine, Zerit), and nevirapine (Viramune). KS was diagnosed based on clinical grounds

CROI: High rate of virologic failure on once-daily combination of ...  -  Mar 8, 2007
Aidsmap,...randomised, open-label clinical trial conducted at several centres in France, which compared a twice-daily combination of nevirapine (Viramune,

CROI: Efavirenz-based ART more effective than nevirapine-based ART ...  -  Feb 27, 2007
Aidsmap,This was one of the largest population-based studies to date comparing the efficacy of efavirenz (Sustiva) versus nevirapine (Viramune), with over 2800

CROI: SMART analysis reveals slightly elevated risk of ...  -  Feb 26, 2007
Aidsmap,Notably, participants whose baseline regimens including the NNRTI nevirapine (Viramune) had a HR of 9.29. In the continuous therapy arm, researchers noted

Single Patient Shows Baraclude May Be Linked to Risk for Resistant HIV  -  Feb 26, 2007
Medscape (subscription)The patient (male, aged 31 years) received combination zidovudine (Retrovir; GlaxoSmithKline), lamivudine, and nevirapine (Viramune; Boehringer Ingelheim)

Data Published In AIDS Show Viramune (nevirapine) Achieves Durable ...  -  Feb 5, 2007
Medical News Today (press release),Patients were then randomized to replace their protease inhibitor with Viramune twice daily (n=155), efavirenz once daily (n=156) or abacavir twice daily

Data Published in AIDS Show Viramune(R) (nevirapine) Achieves ...  -  Jan 31, 2007
Earthtimes.orgPatients were then randomized toreplace their protease inhibitor with VIRAMUNE twice daily (n=155), efavirenzonce daily (n=156) or abacavir twice daily

Data Published in AIDS Show Viramune(R) (nevirapine) Achieves ...  -  Jan 31, 2007
Juraforum.de,An intent-to-treat (ITT) analysis of patients originallyrandomized to switch from their protease inhibitor to VIRAMUNE,efavirenz or abacavir showed that

APS: Data Published in AIDS Show Viramune(R) (nevirapine) ........  -  Jan 31, 2007
ANP Pers Support,...in the abacavir and VIRAMUNE arms occurred in the first weeks of the study. The most. rash in the VIRAMUNE arm. While in the VIRAMUNE group adverse events

Women experience rapid fall in genital secretion of HIV after ...  -  Feb 19, 2007
Aidsmap,...cells/mm 3 and were provided with an antiretroviral regimen consisting of 3TC (lamivudine, Epivir), d4T (stavudine, Zerit) and nevirapine (Viramune).

Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose  -  Feb 15, 2007
MedIndia,Once-daily nevirapine (Viramune) is associated with a higher risk of rash, leading to treatment discontinuation or interruption, than twice-daily dosing of

Cipla wins tentative nod for HIV combo drugs  -  Feb 6, 2007
India Infoline.com,...to sell a copy of GlaxoSmithKline Plc's Combivir two-part treatment combined with Boehringer Ingelheim GmbH's Viramune, according the US drug regulator.

FDA Announces Tentative Approval of Triple Drug Fixed Dose Combination  -  Feb 6, 2007
PharmaLive.com (press release),...the active ingredients in the widely used antiretroviral drugs Epivir (lamivudine), Retrovir (zidovudine) and Viramune (nevirapine).

Boehringer Says Study Supports its AIDS Drug  -  Jan 26, 2007
Therapeutics Daily (subscription) (press release),Nevirapine, sold under the brand name Viramune by privately held Boehringer Ingelheim, had sales of 288 million euros ($372 million) in 2005.

Merck, Pfizer HIV Drugs May Spark a Second Revolution (Update1)  -  Feb 15, 2007
BloombergK103N allows viruses to resist not only Bristol's Sustiva, but the whole class of drugs related to it, including Pfizer's Rescriptor and Viramune,

(PRN) - Tullow Oil plc Trading Statement and Operational Update ...  -  Jan 31, 2007
Bolsamania.com,...(PRN) - Data Published in AIDS Show Viramune(R) (nevirapine) Achieves Durable Benefit in Switch Patients ... [+]. (PRN) - comScore Networks Releases Top Web

Post-Peripartum Use of Viramune Safe After Six-Month Wait  -  Jan 11, 2007
MedPage Today,11 -- For women in developing countries who are HIV-positive, a dose of Viramune (nevirapine) during labor to prevent mother-to-child viral transmission

Delay with AIDS drug restores effectiveness  -  Jan 14, 2007
Daily Times,Implementing this policy can improve the health of women who need AIDS treatment.�Nevirapine is sold under the brand name Viramune. reuters.

Delaying AIDS Treatment may Improve Outcome  -  Jan 12, 2007
Ivanhoe,Doctors give HIV-positive women the drug nevirapine (Viramune) once during labor to reduce the chance they will pass the virus to their child.

Delay with AIDS drug restores effectiveness -study  -  Jan 10, 2007
Reuters AlertNet,...can improve the health of women who need AIDS treatment." Nevirapine is sold under the brand name Viramune by the privately held Boehringer Ingelheim.

Boehringer Ingelheim`s Patent Rights Are No Obstacle To Access To ...  -  Nov 29, 2006
Medical News Today (press release),On the occasion of World Aids Day 2006 Boehringer Ingelheim stated that its patent rights to Viramune® (nevirapine) do not prevent access to this medication

World AIDS Day 2006 – Boehringer Ingelheim`s patent rights are no ...  -  Nov 28, 2006
WebWire (press release),Ingelheim/Germany, 28 November 2006 - On the occasion of World Aids Day 2006 Boehringer Ingelheim stated that its patent rights to Viramune® (nevirapine) do

Aids drugs for Africa deal is off as pharma giants pull out  -  Dec 2, 2006
Independent,A Boehringer spokeswoman said the company provided free drugs though schemes such as the Viramune donation programme. Viramune stops HIV- positive mothers

Communications Media Promotes Darren Martino  -  Dec 12, 2006
PharmaLive.com (press release),Darren currently has planning responsibilities for Lustra, Topicort, U-Kera-E, Ovide, Tracleer, Aptivus and Viramune. Please join me in congratulating

Kenya: Rethinking Aids Prevention - Back to Basics of ABC  -  Dec 14, 2006
AllAfrica.com,...providing clean needles to intravenous drug users, and prevention of mother-to-child transmission using the drug Nevirapine (Viramune).

Black Market Dispenses HIV Drugs and Risk Treatment's cost and ...  -  Nov 29, 2006
Public Integrity,..."Nevirapine," he explains, using the generic name for the brand-name antiretroviral drug Viramune. The price: 35 Kenyan shillings, the equivalent of 49

Management of Antiretroviral Toxicities and HCV Coinfection  Nov 2, 2006
Abstract H1064. Viramune product insert. ... docBase=renetnt&folderPath=/Prescribing+Information/PIs/Viramune/Viramune.pdf. Accessed October 6, 2006. ... -Medscape (subscription) Aptivus®(tipranavir) Demonstrates Durable Response Through Nearly ...  Oct 15, 2006
Apart from Aptivus® (tipranavir), Viramune® (nevirapine) is a product of original research done at Boehringer Ingelheim. Viramune ... -Medical News Today (press release), PROTEST: Boehringer defends animal treatment in wake of small ...  Oct 28, 2006
While Ms. McGuire said Boehringer would like to develop its medicines, such as its HIV treatment Viramune, without animal testing, using animals is still the ... -Ridgefield Press, ARV drugs may also help fight malaria  Oct 10, 2006
Therapies which included nelfinavir (Viracept), amprenavir (Agenerase) and the NNRTI nevirapine (Viramune) did not inhibit the growth of the malaria parasite. ... -SABC News, In resource limited settings, second-line strategies need to be ...  Oct 16, 2006
A single-pill, fixed-dose combination (FDC) of stavudine (d4T), lamivudine (3TC), and nevirapine (Viramune) is produced much more cheaply than the equivalent ... -Aidsmap, Antiretroviral Drugs: A Shot in the Arm to Fight Malaria?  Oct 12, 2006
The presence of nelfinavir (Viracept), amprenavir (Agenerase) and the NNRTI nevirapine (Viramune) in thereapies did not hamper the proliferation of the ... -MedIndia, Communications Media Promotes Darren Martino  -  12 Dec 2006
PharmaLive.com (press release),Darren currently has planning responsibilities for Lustra, Topicort, U-Kera-E, Ovide, Tracleer, Aptivus and Viramune. Please join me in congratulating

Boehringer Ingelheim`s Patent Rights Are No Obstacle To Access To ...  -  Nov 29, 2006
Medical News Today (press release),On the occasion of World Aids Day 2006 Boehringer Ingelheim stated that its patent rights to Viramune® (nevirapine) do not prevent access to this medication

World AIDS Day 2006 – Boehringer Ingelheim`s patent rights are no ...  -  Nov 28, 2006
WebWire (press release),Ingelheim/Germany, 28 November 2006 - On the occasion of World Aids Day 2006 Boehringer Ingelheim stated that its patent rights to Viramune® (nevirapine) do

Aids drugs for Africa deal is off as pharma giants pull out  -  Dec 2, 2006
Independent,A Boehringer spokeswoman said the company provided free drugs though schemes such as the Viramune donation programme. Viramune stops HIV- positive mothers

24-week Results From Aptivus® (tipranavir) RESIST Studies ...  -  Nov 22, 2006
Medical News Today (press release),VIRAMUNE was the first member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV drugs on the market.

Black Market Dispenses HIV Drugs and Risk Treatment's cost and ...  -  Nov 29, 2006
Public Integrity,..."Nevirapine," he explains, using the generic name for the brand-name antiretroviral drug Viramune. The price: 35 Kenyan shillings, the equivalent of 49

Stavudine, didanosine and AZT pose diabetes risk in D:A:D study  -  Nov 20, 2006
Aidsmap,Nevirapine (Viramune) appeared to have a protective effect, with a reduced risk of 11% for every year spent on the drug and, at reported above,

Long-Term Data Show Aptivus(R) (tipranavir) Continues to ...  -  Nov 15, 2006
Drug Newswire (press release),Apart from Aptivus(R) (tipranavir), Viramune(R) (nevirapine) is a product of original research done at Boehringer Ingelheim. nevirapine was the first member

Pharma majors pull up generic AIDS buyers  Aug 20, 2006
Ranbaxy and other firms are also big exporters. BI claims it has invented nevirapine and nevirapine hemihidrate, sold under the brand name of Viramune. ... -Times of India

COMUNICADO: Tipranavir Achieves Virologic and Immunologic ...  Aug 14, 2006
Apart from APTIVUS(R), VIRAMUNE(R) (nevirapine) is a product of original research done at Boehringer Ingelheim. VIRAMUNE(R) was ... -Europa Press

GSK Drops AIDS Drug Patent  Aug 21, 2006
...lower price. BI developed the AIDS drugs nevirapine and nevirapine hemihydrate, which are sold under the brand name Viramune. The ... -Red Herring

Ranbaxy presents bioequivalence data on two paediatric fixed dose ...  Aug 16, 2006
Although a recent Thai study found that splitting adult fixed dose triple combination tablets that contain nevirapine (Viramune) may provide the appropriate ... -Aidsmap

Large analysis shows benefits of starting treatment with efavirenz  Aug 22, 2006
...with efavirenz and two nucleoside reverse transcriptase inhibitors (NRTIs), the investigators found that patients starting with nevirapine (Viramune) were more ... -Aidsmap

Tipranavir Achieves Virologic And Immunologic Improvements In HIV ...  Aug 20, 2006
Apart from Aptivus®, Viramune® (nevirapine) is a product of original research done at Boehringer Ingelheim. Viramune® was the ... -Medical News Today

Genetics associated with risk of severe allergic reaction to ...  Aug 10, 2006
Nevirapine (Viramune) hypersensitivity is much more likely in geographical populations with certain genes, suggests Italian research published in the August ... -Aidsmap

Thailand `Confident' AIDS Infections Will Fall, Thaksin Says  Aug 18, 2006
...triple-drug combination of versions of Bristol-Myers Squibb Co.'s Zerit, GlaxoSmithKline Plc's Epivir and Boehringer Ingelheim GmbH's Viramune, the bank said. ... -Bloomberg

IAC: Micronutrients Improve Immune Function In HIV  Aug 15, 2006
340 patients with very low CD4 counts -- at the beginning, 66% had fewer than 50 cells per microliter of blood -- to get HAART with Viramune (nevirapine), 3TC ... -MedPage Today

News Tips From Johns Hopkins Medicine: XVI International ...  Aug 12, 2006
Drug combinations used included treatment with either stavudine (d4T) or zidovudine (AZT) plus lamivudine (3TC), plus nevirapine (Viramune) or efavirenz ... -AScribe



International Psychopharmacology Research  May 13, 2006
De Vries and colleagues (2003) reported on the results of a study assessing plasma nevirapine (Viramune) concentrations and plasma HIV-1 RNA response in ... - Psychiatric Times





Ultra-sensitive test reveals highly variable patterns of NNRTI ...  11 Apr 2006
This confirms that patients who fail NNRTI-based treatment or take single-dose nevirapine (Viramune) to prevent mother-to-child tranmission of HIV may be at ... - Aidsmap

Wide variability in drug levels casts doubt on the practicality of ...  Mar 28, 2006
The four patients taking efavirenz (Sustiva) had values of 7, 13, 29 and 51%, while the one patient taking nevirapine (Viramune) had an ICV of 25%. ... - Aidsmap

Infinity Announces Three Leadership Promotions  Mar 30, 2006
...and developing several first-in-class agents including, most recently, Velcade®, a proteasome inhibitor for cancer therapy and before that, Viramune® for the ... - Yahoo! News

ABBOTT STATEMENT ON ADVANCING PEDIATRIC HIV TREATMENT IN ...  Mar 13, 2006
Once-daily lopinavir/ritonavir should not be taken with Agenerase(R), Sustiva(R), Viracept(R), Viramune(R), Dilantin(R), Phenobarbital or Tegretol(R). ... - ITNews

Harper’s magazine publishes controversial AIDS story  Mar 13, 2006
...titled “Out of Control: AIDS and the Corruption of Medical Science,� focuses on a recent clinical trial of the anti-HIV drug Viramune among pregnant women ... - The Advocate

Study finds no link between brain-penetrating antiretroviral drugs ...  Mar 21, 2006
...shown that these are AZT (zidovudine, Retrovir), d4T (stavudine, Zerit), 3TC (lamivudine, Epivir), abacavir (Ziagen), nevirapine (Viramune), efavirenz (Sustiva ... - Aidsmap

Abbott Statement on Advancing Pediatric HIV Treatment in ...  Mar 13, 2006
Once- daily lopinavir/ritonavir should not be taken with Agenerase®, Sustiva®, Viracept®, Viramune®, Dilantin®, Phenobarbital or Tegretol®. ... - Yahoo! News



Medivir: Candidate Drug Designated  Feb 9, 2006
...currently amount to around SEK 8 billion and the market is dominated by two products, Sustiva (Bristol Myer Squibb) and Viramune (Boehringer Ingelheim). ... - Genetic Engineering News,

CROI: etravirine (TMC125) and darunavir (TMC114) in treatment ...  Feb 13, 2006
...in EC 50 (50% maximum effective concentration) to etravirine was 1.7, compared with about 40 for efavirenz (Sustiva) and about 60 for nevirapine (Viramune). ... - Aidsmap,

Medivir: Candidate Drug Designated  09 Feb 2006
...currently amount to around SEK 8 billion and the market is dominated by two products, Sustiva (Bristol Myer Squibb) and Viramune (Boehringer Ingelheim). ... - Genetic Engineering News

Multi-component drug delivery system: An emerging trend  Feb 8, 2006
Non-nucleoside Reverse Transcriptase Inhibitors (NnRTIs), which include delavirdine (Rescriptor), efavirenz (Sustiva), and nevirapine (Viramune). ... - Express Pharma Pulse

Almost a third of Indian patients make changes to first-line ...  Jan 19, 2006
Even so, the study does make a number of interesting observations — including a high rate of nevirapine (Viramune)-related liver toxicity in persons also ... - Aidsmap

Study compares HIV treatment options  Jan 31, 2006
...day. If intolerable side effects were felt from the efavirenz, nevirapine (Viramune) was administered twice daily in its place. ... - myDNA.com

ICAAC: Nevirapine’s manufacturer examines rates of liver ...  Jan 9, 2006
The high rates of liver side-effects seen in a major study of nevirapine (Viramune) may have been driven by unusual results from one study centre, according to ... - Aidsmap

Get News from  Jan 8, 2006
This product is the first generic version of the approved product, Viramune Oral Suspension, 50 mg /5 ml, manufactured by Boehringer Ingelheim Pharmaceuticals. ... - Myiris.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional